Washington, DC
4 risk indicators measuring financial stability and operational resilience
Sign in with your work email to view Tuckman-Chang indicators
Sign In — Free (10 views/day)Friends of Cancer Research, founded in 1996, is a community nonprofit in the Medical Research sector that reported $7.2M in total revenue in fiscal year 2023. The organization ran a surplus of $1.9M, a strong 27% operating margin.
TO DRIVE COLLABORATION AMONG PARTNERS FROM EVERY HEALTHCARE SECTOR TO POWER ADVANCES IN SCIENCE, POLICY AND REGULATION THAT SPEED LIFE-SAVING TREATMENTS TO PATIENTS.
Science Policy: FRIENDS OF CANCER RESEARCH DRIVES COLLABORATION AMONG PARTNERS FROM EVERY HEALTHCARE SECTOR TO POWER ADVANCES IN SCIENCE, POLICY AND REGULATION THAT SPEED LIFE-SAVING TREATMENTS TO...
Science Policy: FRIENDS OF CANCER RESEARCH DRIVES COLLABORATION AMONG PARTNERS FROM EVERY HEALTHCARE SECTOR TO POWER ADVANCES IN SCIENCE, POLICY AND REGULATION THAT SPEED LIFE-SAVING TREATMENTS TO PATIENTS.
Meetings and Professional Development: Friends of Cancer Research brings together leaders in cancer drug development, federal health and regulatory agencies, academic research, the private sector...
Meetings and Professional Development: Friends of Cancer Research brings together leaders in cancer drug development, federal health and regulatory agencies, academic research, the private sector, and patient advocates for focused discussions on key issues surrounding the development and regulation of cancer drugs and therapies.
Communication: THE Organization PROVIDES INDEPTH COVERAGE OF THE EVENTS, TRENDS, AND ISSUES THAT AFFECT the public healthcare INDUSTRY.
Financial Health Score (300–850) · Liquidity · Solvency · Sustainability · Efficiency
Sign in to view Trantor Score and financial metrics
Liquidity (40%) • Solvency (30%) • Sustainability (20%) • Efficiency (10%)
Sign In — Free (10 views/day)| 2023 | 2022 | Change | |
|---|---|---|---|
| Revenue | $7,186,730 | $6,784,533 | +0.1% |
| Expenses | $5,245,007 | $4,975,120 | +0.1% |
| Net Income | $1,941,723 | $1,809,413 | +0.1% |
Comprehensive financial analysis: Altman Z-Score, liquidity, solvency, sustainability, efficiency, and growth metrics
Financial Distress Indicator
Liquidity & Cash Position
Sign in to view all financial metrics
Altman Z-Score • Liquidity Ratios • Solvency Analysis • Growth Indicators • Efficiency Metrics
Sign In| Name | Title | Hours/Week | Role | Reportable Comp | Other Comp | Total |
|---|---|---|---|---|---|---|
| Jeff Allen PhD | President & CEO | 40.00 |
Officer
Director
|
$622,957 | $115,666 | $738,623 |
| Ryan Hohman JD | VP-Public Affairs | 40.00 |
|
$285,934 | $20,833 | $306,767 |
| Mark Stewart PhD | VP-Science Policy | 40.00 |
|
$258,113 | $16,275 | $274,388 |
| Heather Chaney | VP-Operations | 40.00 |
|
$207,967 | $20,012 | $227,979 |
| Hillary Andrews | Dir.-Reg & Res Par | 40.00 |
|
$161,668 | $16,303 | $177,971 |
| linda ostermann | Dir.-Grant & Oper | 40.00 |
|
$150,093 | $14,773 | $164,866 |
| Brittany McKelvey | Dir.-Reg Affairs | 40.00 |
|
$132,947 | $5,623 | $138,570 |
| Pennie Abramson PhD | Director | 0.50 |
Director
|
$0 | $0 | $0 |
| Carolyn Aldige | Director | 0.50 |
Director
|
$0 | $0 | $0 |
| Anna D Barker PhD | Exec. Committee | 0.50 |
Officer
Director
|
$0 | $0 | $0 |
| Edward Sanghyun Kim MD MBA | Director | 0.50 |
Director
|
$0 | $0 | $0 |
| Roy Herbst MD PhD | Director | 0.50 |
Director
|
$0 | $0 | $0 |
| Ellen Sigal PhD | Chair & Founder | 0.50 |
Officer
Director
|
$0 | $0 | $0 |
| Marlene Malek RN | Vice Chair | 0.50 |
Officer
Director
|
$0 | $0 | $0 |
| Sudip Parikh PhD | Exec. Committee | 0.50 |
Officer
Director
|
$0 | $0 | $0 |
| Margaret Foti PhD MD | Exec. Committee | 0.50 |
Officer
Director
|
$0 | $0 | $0 |
| David Mitchell | Exec. Committee | 0.50 |
Officer
Director
|
$0 | $0 | $0 |
| Richard Schilsky MD | Exec. Committee | 0.50 |
Officer
Director
|
$0 | $0 | $0 |
| Elizabeth Thompson | Director | 0.50 |
Director
|
$0 | $0 | $0 |
| Edward J Benz Jr MD | Director | 0.50 |
Director
|
$0 | $0 | $0 |
| Margaret Anderson | Director | 0.50 |
Director
|
$0 | $0 | $0 |
| Year | Revenue | Expenses | Assets | Net Income |
|---|---|---|---|---|
| 2024 | No data | No data | No data | No data |
| 2023 | $7,186,730 | $5,245,007 | $19,663,708 | $1,941,723 |
| 2022 | $6,784,533 | $4,975,120 | $13,380,551 | $1,809,413 |
| 2021 | $5,525,309 | $3,563,423 | $13,600,990 | $1,961,886 |
| 2020 | $4,973,258 | $3,566,774 | $10,464,081 | $1,406,484 |
| 2019 | $5,295,880 | $3,786,105 | $8,476,969 | $1,509,775 |
| 2018 | $4,413,385 | $3,516,178 | $6,367,801 | $897,207 |
Compare Friends of Cancer Research with other nonprofits in District of Columbia and across the country.